Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #1859781

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
14,906,000 USD
713,000 USD
Cash flows from (used in) operations before changes in working capital
42,750,000 USD
89,485,000 USD
Increase (decrease) in working capital
4,961,000 USD
3,916,000 USD
Adjustments for decrease (increase) in trade and other receivables
5,918,000 USD
7,040,000 USD
Adjustments for increase (decrease) in trade and other payables
5,193,000 USD
7,019,000 USD
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
19,610,000 USD
8,314,000 USD
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
467,000 USD
1,039,000 USD
Purchase of interests in associates
USD
329,000 USD
Payments for development project expenditure
2,530,000 USD
1,583,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of bonds, notes and debentures
USD
142,825,000 USD
Payments for debt issue costs
USD
2,649,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.